NASDAQ
228.74USD
-0.16 (-0.07%)
We have scored 3 news catalysts on Seagen Inc. (SGEN) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.20). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
43.2B
P/E
—
EPS
—
Beta
0.32
52W range
126.47-228.96
Day range
228.74–228.96
Open
228.93
Prev close
228.90
Volume
19.4M
Avg volume
1.6M
Dividend
0.00
IPO
2001-03-09
No scored news tagged SGEN or its network in the window yet.
Show more SGEN articles →Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Seagen Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Seagen Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for SGEN: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
